Sanofi Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results ...
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...
EuropaWire1d
Sanofi Accelerates Chlamydia Prevention with Fast Tracked mRNA Vaccine
Sanofi’s mRNA vaccine candidate for chlamydia has been granted fast track designation by the US FDA, reflecting its promising potential to addr ...
The Manila Times2d
Press Release: Chlamydia vaccine candidate granted fast track designation by the US FDA
The development of this vaccine candidate is part of the Translational Science Hub, a partnership with the Queensland Government, Griffith University, and the University of Queensland, connecting ...
pharmaphorum2d
FDA starts review of Sanofi's MS hope tolebrutinib
The FDA review – which is due to be completed by 28th September – revolves around the results of the HERCULES trial which ...
Taiwan News3d
Press Release: Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
Tolebrutinib was granted breakthrough therapy designation by the FDA based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive MS ...
Sanofi Availability of the Q1 2025 Aide mémoire
Aide mémoire Paris, France - March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First ...
Press Release: Availability of the Q1 2025 Aide mémoire
March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First quarter 2025 (sanofi.com) As for each quarter, Sanofi prepared ...